Literature DB >> 19726414

Progression in prediagnostic Huntington disease.

Jason Rupp1, Tanya Blekher, Jacqueline Jackson, Xabier Beristain, Jeanine Marshall, Siu Hui, Joanne Wojcieszek, Tatiana Foroud.   

Abstract

OBJECTIVE: To examine rates of decline in individuals at risk for Huntington disease (HD).
METHODS: 106 individuals at risk for HD completed a battery of neurocognitive, psychomotor and oculomotor tasks at two visits, approximately 2.5 years apart. Participants were classified as: (1) without the CAG expansion (normal controls, NC; n=68) or (2) with the CAG expansion (CAG+; n=38). The CAG+ group was further subdivided into those near to (near; n=19) or far from (far; n=19) their estimated age of onset. Longitudinal performance in the CAG+ group was evaluated with a repeated measures model with two main effects (time to onset, visit) and their interaction. Analysis of covariance was employed to detect differences in longitudinal performance in the three groups (NC, near and far).
RESULTS: In the CAG+, the interaction term was significant (p < or = 0.02) for four measures (movement time, alternate button tapping, variability of latency for a memory guided task and percentage of errors for a more complex memory guided task), suggesting the rate of decline was more rapid as subjects approached onset. Longitudinal progression in the three groups differed for several variables (p<0.05). In most, the near group had significantly faster progression than NC; however, comparisons of the NC and far groups were less consistent.
CONCLUSIONS: Different patterns of progression were observed during the prediagnostic period. For some measures, CAG+ subjects closer to estimated onset showed a more rapid decline while for other measures the CAG+ group had a constant rate of decline throughout the prediagnostic period that was more rapid than in NC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726414      PMCID: PMC2872788          DOI: 10.1136/jnnp.2009.176982

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  32 in total

1.  Identification of an oculomotor biomarker of preclinical Huntington disease.

Authors:  C V P Golding; C Danchaivijitr; T L Hodgson; S J Tabrizi; C Kennard
Journal:  Neurology       Date:  2006-04-19       Impact factor: 9.910

2.  Early cognitive deficits in Swedish gene carriers of Huntington's disease.

Authors:  Tarja-Brita Robins Wahlin; Anders Lundin; Keith Dear
Journal:  Neuropsychology       Date:  2007-01       Impact factor: 3.295

3.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

4.  Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.

Authors:  V Hahn-Barma; B Deweer; A Dürr; C Dodé; J Feingold; B Pillon; Y Agid; A Brice; B Dubois
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

5.  Saccades in presymptomatic and early stages of Huntington disease.

Authors:  T Blekher; S A Johnson; J Marshall; K White; S Hui; M Weaver; J Gray; R Yee; J C Stout; X Beristain; J Wojcieszek; T Foroud
Journal:  Neurology       Date:  2006-07-19       Impact factor: 9.910

6.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

7.  Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers.

Authors:  S C Kirkwood; E Siemers; J C Stout; M E Hodes; P M Conneally; J C Christian; T Foroud
Journal:  Arch Neurol       Date:  1999-05

8.  Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease.

Authors:  G M de Boo; A Tibben; J B Lanser; A Jennekens-Schinkel; J Hermans; A Maat-Kievit; R A Roos
Journal:  Arch Neurol       Date:  1997-11

9.  Saccadometry: a new tool for evaluating presymptomatic Huntington patients.

Authors:  Chrystalina A Antoniades; Pat M E Altham; Sarah L Mason; Roger A Barker; Roger Carpenter
Journal:  Neuroreport       Date:  2007-07-16       Impact factor: 1.837

10.  Evidence for specific cognitive deficits in preclinical Huntington's disease.

Authors:  A D Lawrence; J R Hodges; A E Rosser; A Kershaw; C ffrench-Constant; D C Rubinsztein; T W Robbins; B J Sahakian
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

View more
  24 in total

1.  Huntington's disease: changes in saccades and hand-tapping over 3 years.

Authors:  Chrystalina A Antoniades; Zheyu Xu; Sarah L Mason; R H S Carpenter; Roger A Barker
Journal:  J Neurol       Date:  2010-06-29       Impact factor: 4.849

2.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

Review 3.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

Review 4.  Cognitive impairment in Huntington disease: diagnosis and treatment.

Authors:  Jane S Paulsen
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

5.  Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease.

Authors:  Jason Rupp; Mario Dzemidzic; Tanya Blekher; John West; Siu Hui; Joanne Wojcieszek; Andrew J Saykin; David A Kareken; Tatiana Foroud
Journal:  J Neurol       Date:  2011-08-18       Impact factor: 4.849

6.  Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.

Authors:  Robert Christian Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine Donata Wolf; Philipp Arthur Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  Hum Brain Mapp       Date:  2011-08-25       Impact factor: 5.038

7.  Cognitive reserve and brain reserve in prodromal Huntington's disease.

Authors:  Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2013-05-23       Impact factor: 2.892

Review 8.  Eye movements in patients with neurodegenerative disorders.

Authors:  Tim J Anderson; Michael R MacAskill
Journal:  Nat Rev Neurol       Date:  2013-01-22       Impact factor: 42.937

9.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

10.  Everyday cognition in prodromal Huntington disease.

Authors:  Janet K Williams; Ji-In Kim; Nancy Downing; Sarah Farias; Deborah L Harrington; Jeffrey D Long; James A Mills; Jane S Paulsen
Journal:  Neuropsychology       Date:  2014-07-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.